PAPER Martin BA, Allen PA

Where do we stand on the relationship between tau biomarkers and mild cognitive impairment?

Quant Imaging Med Surg. 2013 Aug;3(4):189-91. PubMed: 24040613

Kumar Sambamurti on Proteomics Point to RNA Splicing Defects in Alzheimer’s

COMMENT This is a truly exciting advance. While the small RNA world has captured the attention of the field, the global spicing failure is very novel and has been ignored since the days of KPI containing APP forms. It is curious that the authors saw a large incre

Jürgen Götz on Proteomics Point to RNA Splicing Defects in Alzheimer’s

COMMENT This is interesting also in the context of our finding that in the presence of tau the splicing factor SFPQ is relocalized from the nucleus to the cytoplasm. j.goetz 0 Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's

RG7129

THERAPEUTICS Roche RO5508887 BACE Inhibitor Small Molecule Amyloid-Related Three Phase 1 trials have been completed. In January 2012, a trial conducted in Strasbourg, France, concluded a test of RG7129 in 50 healthy men to assess safety and pharmacological parameters

Lanabecestat

THERAPEUTICS AstraZeneca Eli Lilly & Co. AZD3293 LY3314814 BACE inhibitor Small Molecule Amyloid-Related In December 2012, AstraZeneca started a Phase 1 study that evaluated the safety and pharmacological effects of single doses of oral AZD3293 in 72 healthy volun

Elenbecestat

THERAPEUTICS Biogen Eisai Co., Ltd. E2609 BACE inhibitor Small Molecule Amyloid-Related By March 2015, eight Phase 1 trials had been completed to evaluate the safety and pharmacology of elenbecestat in nearly 500 healthy volunteers and people with early Alzheimer'